Aarestrup F M
APMIS Suppl. 2000;101:1-48.
14.1
This thesis is based on a number of monitoring and research programmes initiated at the Danish Veterinary Laboratory with the aim to determine the occurrence, selection and spread of resistance to antimicrobial agents used for growth promotion. The thesis gives a brief overview of the use, consumption, function and benefit of antimicrobial growth promoters and a more thorough description of the potential resistance problems arising by the use of these agents. 14.2 THE USE OF ANTIMICROBIAL AGENTS IN A HISTORICAL PERSPECTIVE: Soon after the introduction of antimicrobial agents for therapy of bacterial infections in humans and animals, the growth promoting effect of antimicrobial agents was observed, and since the beginning of the 1950'ties antimicrobial agents have been included in feed for food animals as a way to improve growth and reduce production costs. 14.3 CONSUMPTION OF ANTIMICROBIAL GROWTH PROMOTERS: Exact figures on the consumption of antimicrobial agents for clinical and growth promoting purposes are very difficult to get, and estimates are only available for a few countries. In Denmark, the total annual consumption of antimicrobial agents for growth promotion increased from 67 tonnes to 116 tonnes from 1989 to 1995. After the ban on avoparcin in 1995 the total consumption of growth promoters decreased to 94 tonnes. An increase up to 107 tonnes took place during 1996 and 1997, but during 1998, the consumption decreased to approximately 49 tonnes. The data that are available for different countries show that the use of antimicrobial agents for growth promotion normally equals or exceeds the usage of antimicrobial agents for therapy for food animals. Based on the information available, it can be estimated that the financial sale of antimicrobial agents for animals amounts to approximately 25% to 35% of the world-wide sale, of which the use of antimicrobial agents as feed additives is at least 50%. 14.4 MODE OF ACTION OF ANTIMICROBIAL GROWTH PROMOTERS: The mode of action of antimicrobial growth promoters is not fully understood. However, the main effects are believed to be a reduction of the growth of bacteria in the intestinal tract and thereby less microbial degradation of useful nutritients, and the prevention of infections with pathogenic bacteria. 14.5 BENEFIT FROM THE USE OF ANTIMICROBIAL GROWTH PROMOTERS: Numerous studies on the economic benefit of the use of antimicrobial growth promoters have been performed. The growth response is normally larger in young animals than in older animals. Large variations in the estimates have been observed, but in general a improvement in growth rate and feed utilisation has been observed. 14.6 SUSCEPTIBILITY AND RESISTANCE TO ANTIMICROBIAL GROWTH PROMOTERS: The definition of a bacterium as susceptible or resistant to an antimicrobial agent ultimately depends on clinical outcome. Since the exact mode of action of antimicrobial growth promoters are not known, the only way to define break points is based on the population distributions of susceptibilities to different agents. For antimicrobial agents used both for therapy and growth promotion the break points for therapy have been used. For avilamycin, avoparcin, flavomycin, monensin and salinomycin, that are used for growth promotion only, tentative break points based on population distributions have to be defined. The tentative break points for avoparcin and avilamycin have been confirmed by cross-resistance to other antimicrobial agents belonging to the same class and the presence of resistance mechanisms. 14.7 OCCURRENCE OF AND SELECTION FOR RESISTANCE TO ANTIMICROBIAL AGENTS USED FOR GROWTH PROMOTION: Information on the occurrence of resistance is needed to guide policy and detect changes that require intervention strategies. In 1995, a continuous monitoring of antimicrobial resistance in bacteria isolated from food animals was established in Denmark. Among food animals three categories of bacteria (indicator bacteria, zoonotic bacteria and animal pathogens) are continuously isolated from broilers, cattle and pigs and tested for susceptibility to antimicrobial agents used for therapy and growth promotion by disc diffusion or MIC-determinations. In all known cases antimicrobial resistance has emerged following the introduction of new antimicrobial compounds for therapy. The occurrence of resistance to antimicrobial agents used for growth promotion indicates that resistance will also emerge following the introduction of antimicrobials for growth promotion. Comparison of the occurrence of resistance among reservoirs with different usage of antimicrobial agents for growth promotion also shows that the occurrence of resistance will follow the usage. (ABSTRACT TRUNCATED)
14.1
本论文基于丹麦兽医实验室发起的多项监测和研究项目,旨在确定用于促进生长的抗菌药物的耐药性发生、选择和传播情况。本文简要概述了抗菌促生长剂的使用、消费、功能和益处,并更全面地描述了使用这些药物可能产生的耐药性问题。14.2 抗菌药物使用的历史回顾:在人类和动物细菌感染治疗中引入抗菌药物后不久,人们就观察到了抗菌药物的促生长作用。自20世纪50年代初以来,抗菌药物就被添加到食用动物饲料中,以提高生长速度并降低生产成本。14.3 抗菌促生长剂的消费情况:很难获得用于临床和促生长目的的抗菌药物消费的确切数据,只有少数国家有相关估计数据。在丹麦,1989年至1995年期间,用于促生长的抗菌药物年总消费量从67吨增加到116吨。1995年阿伏帕星被禁用后,促生长剂的总消费量降至94吨。1996年和1997年消费量增加至107吨,但1998年消费量降至约49吨。不同国家可得的数据表明,用于促生长的抗菌药物使用量通常等于或超过用于食用动物治疗的抗菌药物使用量。根据现有信息估计,动物用抗菌药物的销售额约占全球销售额的25%至35%,其中作为饲料添加剂使用的抗菌药物至少占50%。14.4 抗菌促生长剂的作用方式:抗菌促生长剂的作用方式尚未完全明确。然而,其主要作用被认为是减少肠道内细菌的生长,从而减少有益营养物质的微生物降解,并预防病原菌感染。14.5 使用抗菌促生长剂的益处:已经进行了许多关于使用抗菌促生长剂经济效益的研究。通常幼龄动物的生长反应比老龄动物更大。估计值存在很大差异,但总体上观察到生长速度和饲料利用率有所提高。14.6 对抗菌促生长剂的敏感性和耐药性:将一种细菌定义为对抗菌药物敏感或耐药最终取决于临床结果。由于抗菌促生长剂的确切作用方式尚不清楚,确定断点的唯一方法是基于对不同药物敏感性的群体分布。对于既用于治疗又用于促生长的抗菌药物,采用治疗的断点。对于仅用于促生长的阿维拉霉素、阿伏帕星、黄霉素、莫能菌素和盐霉素,必须根据群体分布确定暂定断点。阿伏帕星和阿维拉霉素的暂定断点已通过与同一类其他抗菌药物的交叉耐药性以及耐药机制的存在得到证实。14.7 用于促生长的抗菌药物耐药性的发生和选择:需要有关耐药性发生的信息来指导政策制定并检测需要干预策略的变化。1995年,丹麦建立了对从食用动物分离的细菌的抗菌药物耐药性的持续监测。在食用动物中,从肉鸡、牛和猪中持续分离出三类细菌(指示菌、人畜共患病菌和动物病原菌),并通过纸片扩散法或最小抑菌浓度测定法检测它们对用于治疗和促生长的抗菌药物的敏感性。在所有已知案例中,在引入新的治疗用抗菌化合物后都出现了抗菌药物耐药性。对用于促生长的抗菌药物的耐药性出现表明,在引入促生长用抗菌药物后也会出现耐药性。比较不同促生长用抗菌药物使用量的储存库中耐药性的发生情况也表明耐药性的发生将与使用量相关。(摘要截断)